Tell us about yourself and your entrepreneurial journey
I spent the first fourteen years of my career as an engineer inside large organisations — Boeing, Telstra, Wells Fargo, Accenture. The common thread was that I built systems where failure had real consequences: aircraft, telecom networks, financial infrastructure. You learn a particular kind of discipline when the thing you ship cannot quietly break.
At some point that discipline stopped being enough on its own. I wanted to point it at a problem I actually cared about and own the outcome. So I founded Xine Technology Solutions in 2022, and more recently IDMedico <a href="https://jordangazette.com/ge-healthcare-and-rsna-bring-leading-cancer-imaging-expertise-to-africa-to-improve-access-to-cancer-care/”>Healthcare Technologies.
The honest version of the journey is that it’s far less linear than it looks from outside. I’ve repriced a funding round after tough investor feedback, walked away from a partnership that was heading the wrong way, and rebuilt the same product more than once when the first version turned out to be wrong. Entrepreneurship, for me, has mostly been a series of corrections made quickly and without ego.
What are the three biggest and most important entrepreneurial lessons you have learned?
First: say the true thing, especially when it costs you. I once lowered my own company’s valuation after an investor pointed out something I’d have preferred not to hear. That kind of honesty compounds — it’s the only reputation actually worth having.
Second: claims are liabilities. In healthcare especially, the fastest way to destroy a company is to say your product does something it isn’t yet cleared to do. We describe our capabilities as wellness-grade today and clinical-grade only after regulatory clearance, and we hold that line even when blurring it would be easier. The companies that get punished are almost always the ones that overstated.
Third: build for the person, not the demo
It’s easy to make something impressive on a stage. It’s much harder to make something a nurse will still choose to use on a busy Tuesday. Only the second one matters.
What interesting projects are you currently involved in?
Two, mainly. IDMedico is a wearable platform for monitoring chronic blood disorders — we’ve just run our first pilot with thalassemia patients, collecting pre-transfusion readings on a wrist-worn device. Xine is home to SuperID, a decentralised digital identity platform built on open standards, increasingly aimed at the problem of who really controls health data.
The most satisfying recent moment was mundane on paper: six thalassemia patients, day one of a pilot, real readings captured on a device we had reverse-engineered right down to its Bluetooth protocol. Nothing about it was glamorous. It was simply the first time the thing worked in the world instead of in a lab — and that’s the moment every founder is actually chasing.
What inspired you to build IDMedico, and what healthcare problem are you determined to solve?
Thalassemia patients live by their haemoglobin. They need regular transfusions, and the right timing depends on where their haemoglobin sits — but today that number is only checked when they visit a clinic and give blood. Between visits, they are effectively flying blind, and so are their doctors.
The problem I’m determined to solve is the gap between measurements. If we can give patients and clinicians a continuous, non-invasive trend of how haemoglobin is moving — not a diagnosis, a trend — we turn transfusions from a fixed schedule into something responsive to the actual person. That same gap exists across chronic care more broadly. Thalassemia is where we start because the need is acute and the population is underserved, particularly across South Asia and the Middle East.
Can you explain how IDMedico’s AI-powered remote patient monitoring platform works?
At the sharp end it’s a wrist-worn wearable paired with a mobile app
The wearable’s optical sensors capture the raw physiological signals; our software reads them off the device, stores them securely, and turns them into trends a clinician can act on. Consent and data handling are built into the flow from the very first screen, not bolted on afterwards.
I want to be precise about the haemoglobin piece, because precision is the entire game here. Today it is an investigational estimator producing a trend, and we are calibrating it against paired clinical measurements before making any stronger claim. The “AI” is not magic — it’s a model being fit carefully on real, paired data, and it does not ship as a diagnostic until the evidence and the regulators say it can. The platform is deliberately designed so that as that evidence matures, the same device can move from wellness-grade insight to clinically validated monitoring without the patient having to change a thing.
Healthcare has traditionally been reactive. Why do you believe the future lies in preventive, AI-powered healthcare?
Because episodic care is structurally blind. A clinic visit is a single frame from a film. You make decisions off that one frame and hope the rest of the story matched it. For a stable patient that’s usually fine. For someone with a chronic condition, the important information is almost always in what happened between visits — the trend, the drift, the early wobble a single reading can never show.
Continuous monitoring closes that gap
It doesn’t replace the clinician; it hands them the film instead of one frame. AI’s job is to make that stream of data legible — to surface the drift that matters and stay quiet about the noise that doesn’t. Move from reacting to a crisis to noticing the conditions before it, and you change both the cost of care and, far more importantly, the human outcome.
What do you see as the future of AI-powered preventive healthcare?
Over the next decade I think three things happen. Monitoring moves onto the body and into the background, so measurement stops being an event patients have to organise their lives around. The intelligence moves increasingly on-device, so sensitive data doesn’t have to leave the person to be useful. And continuous care becomes the default for chronic conditions — the exception will be the untracked patient, not the tracked one.
The failure mode to avoid is a world of alarms nobody trusts. If preventive AI cries wolf, clinicians will rightly ignore it. So the real work isn’t flashy prediction; it’s earning trust through restraint and evidence. The winners in this space will be quiet and correct, not loud.
Healthcare data is becoming one of the world’s most valuable digital assets
Why is data sovereignty so important?
Because health data is the most intimate record a person has, and right now most people don’t control theirs — it’s scattered across hospitals, labs, apps, and insurers, each holding a copy the patient can’t see or move. That’s a sovereignty problem before it’s ever a security problem. The question “who owns this, and who can I prove it to?” usually has no clean answer today.
For the Middle East specifically, this matters at a national level too. Countries are rightly unwilling to have their citizens’ health records sit in someone else’s jurisdiction. Keeping control of health data with the patient, and within the right borders, is becoming a baseline requirement rather than a nice-to-have. That’s a large part of why I’ve invested so heavily in the identity layer through SuperID.
What cybersecurity risks concern you most in the future of digital healthcare?
Two
The first is ransomware against clinical systems — it’s already happening, and when a hospital’s systems are frozen, the harm is measured in delayed care, not just money. The second, further out, is the quiet one: data being harvested now to be decrypted later, once quantum computing matures. Health records have a long shelf life. Something stolen today can still hurt someone fifteen years from now.
That’s why we designed SuperID to be post-quantum-ready rather than treating it as a problem for another decade. The attacker’s timeline and the patient’s timeline are different, and you have a responsibility to design for the longer one.
How should healthcare organisations balance innovation with patient privacy?
I don’t fully accept the framing that the two are opposed. Most privacy failures aren’t the price of innovation — they’re the price of lazy architecture. If you design so that data stays with the patient, so that systems can prove things without exposing everything, and so that the patient is a participant rather than a subject, you actually get to innovate faster, because you’re not sitting on a liability.
The practical discipline is straightforward: collect less, keep it closer to the person, process on the device wherever you can, and make consent real rather than a checkbox. Do that, and privacy stops being the brake and becomes the thing that lets you move.
How is SuperID transforming the way healthcare digitally operates?
SuperID gives every person a digital identity they genuinely control, built on open W3C standards rather than a single company’s login. In healthcare terms, a patient can hold verifiable credentials — a diagnosis, a prescription, a consent — and share exactly what’s needed with exactly who needs it, provably, without handing over their entire record.
The shift is from institutions holding copies of you, to you holding a verifiable version of yourself that institutions can trust. Recovery, encryption, and the secure messaging between parties are all designed to keep the patient at the centre. It’s early, but the direction is a health system where moving your data safely between a hospital in Riyadh and a clinic in Manchester is something you simply do, not something you have to beg for.
What significant opportunities for digital healthcare innovation do you see in the Middle East?
The Middle East is unusually well-positioned. There’s political will, real capital, national digital-health strategies with genuine momentum, and populations where chronic conditions — including the blood disorders we focus on — are prevalent. Fewer legacy systems also means less to unwind. When a region decides to leapfrog, it can.
Concretely, we hold a MISA license for entry into Saudi Arabia and are building toward a wellness-first launch there, and I’ve been engaging with the innovation ecosystem in Abu Dhabi as well. My read is that the Gulf could become one of the first places where continuous, sovereign, preventive care is simply how the system works — rather than a pilot bolted onto an old one.
What is your vision for global healthcare systems?
A world where care is continuous rather than episodic, where the patient owns and controls their own health data, and where that data can move safely across borders when the patient’s life does. My own family is moving countries this year — the fact that health records don’t travel as easily as people do is something I feel personally, not just professionally.
What is your vision for IDMedico?
To build IDMedico into one of the world’s most trusted AI-powered continuous health monitoring platforms—one that helps shift healthcare from episodic treatment to proactive, personalized, and preventive care. We are starting with chronic blood disorders because the clinical need is immediate and the opportunity to make a meaningful impact is significant. But our vision extends much further. We see a future where continuous physiological monitoring, combined with responsible AI, enables earlier intervention across a wide range of chronic and preventive healthcare use cases.
Our ambition is to create a platform that empowers patients to better understand their health, gives clinicians continuous, evidence-based insights rather than isolated measurements, and helps healthcare systems deliver better outcomes while reducing costs. We will expand only where the science, clinical validation, and regulatory evidence support us. Success for us isn’t defined by the number of features we build, but by becoming a platform that patients trust, clinicians rely on, and healthcare providers adopt with confidence around the world.
What legacy do you hope to leave?
Two things. That I built healthcare technology that was honest — that never claimed more than it had earned, and that patients and clinicians could genuinely trust. And, closer to home, that my children grow up seeing it’s possible to build something serious without cutting the corners that make it worthless. If the work is remembered as careful, and the character behind it as straight, that’s enough for me.
Where can readers connect with you and find out more?
You can learn more about IDMedico here: at idmedico.com.
I regularly share insights on AI in healthcare, digital identity, cybersecurity, preventive healthcare, and entrepreneurship on LinkedIn, and I publish long-form articles on Substack exploring the future of healthcare, decentralized identity, AI, cybersecurity, and emerging technologies.
LinkedIn: https://www.linkedin.com/in/mohammed-galeeb-017a91aa
Substack: https://substack.com/@mohammedgaleeb
